A human monoclonal antibody blocking SARS-CoV-2 infection

dc.creator	Wang, Chunyan
dc.creator	Li, Wentao
dc.creator	Drabek, Dubravka
dc.creator	Okba, Nisreen M. A.
dc.creator	van Haperen, Rien
dc.creator	Osterhaus, Albert D. M. E.
dc.creator	van Kuppeveld, Frank J. M.
dc.creator	Haagmans, Bart L.
dc.creator	Grosveld, Frank
dc.creator	Bosch, Berend-Jan
dc.date.accessioned	2020-05-05T14:32:25Z
dc.date.available	2020-05-05T14:32:25Z
dc.date.issued	2020
dc.description.abstract	The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.	pt_BR
dc.identifier.citation	WANG, C. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nature Communications, [S.l.], v. 11, 2020.	pt_BR
dc.identifier.uri	https://repositorio.ufla.br/handle/1/40581
dc.identifier.uri	https://www.nature.com/articles/s41467-020-16256-y	pt_BR
dc.language	en_US	pt_BR
dc.publisher	Springer Nature	pt_BR
dc.rights	restrictAccess	pt_BR
dc.source	Nature Communications	pt_BR
dc.subject	COVID-19 - Treatment	pt_BR
dc.subject	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	pt_BR
dc.subject	Monoclonal antibody	pt_BR
dc.title	A human monoclonal antibody blocking SARS-CoV-2 infection	pt_BR
dc.type	Artigo	pt_BR

Arquivos

Agora exibindo 1 - 1 de 1